BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 15077226)

  • 1. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
    Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
    Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
    J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of amifostine in autologous stem cell transplant.
    Sastry P; Bhagwat R; Biswas G; Khadwal A; Narayanan P; Bakshi A; Parikh P
    Bone Marrow Transplant; 2006 Jan; 37(1):117-8. PubMed ID: 16273114
    [No Abstract]   [Full Text] [Related]  

  • 4. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
    Cagnoni PJ; Matthes S; Day TC; Bearman SI; Shpall EJ; Jones RB
    Bone Marrow Transplant; 1999 Jul; 24(1):1-4. PubMed ID: 10435726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
    Jones RB; Stockerl-Goldstein KE; Klein J; Murphy J; Blume KG; Dansey R; Martinez C; Matthes S; Nieto Y
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):276-82. PubMed ID: 15077226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
    Phillips GL
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):53-6. PubMed ID: 12577245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amifostine and hematologic effects.
    Sriswasdi C; Jootar S; Giles FJ
    J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection by amifostine of cyclophosphamide-induced myelosuppression.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.